Equity Overview
Price & Market Data
Price: $5.17
Daily Change: -$0.86 / 16.63%
Range: $4.70 - $5.20
Market Cap: $22,589,224
Volume: 165,066
Performance Metrics
1 Week: 34.60%
1 Month: 47.43%
3 Months: -1.01%
6 Months: -49.51%
1 Year: -81.73%
YTD: -28.85%
Company Details
Employees: 18
Sector: Health technology
Industry: Biotechnology
Country: Canada
Details
BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers. It has a license agreement with the University of Maryland, Baltimore County to develop and commercialize soluble CD80 as a biologic agent for the treatment of cancer. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.